Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Terminated 1Available 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3Expanded_access 1

Sponsor

Cancer Type

Lymphoid 4Plasma cell 2Myeloid 2Dermatologic 2Sarcoma 1Other hematologic neoplasm 1Gynecologic 1

Conditions

Multiple Myeloma 47Leukemia, Myeloid, Acute 25Recurrence 21Lymphoma, Large B-Cell, Diffuse 13Sarcoma 9Lymphoma 6Neoplasms, Plasma Cell 5Neoplasm Metastasis 5Glioblastoma 5Endometrial Neoplasms 5Ovarian Neoplasms 4Neurofibrosarcoma 4Neoplasms 4Melanoma 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Non-Hodgkin 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell 3Liposarcoma 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Waldenstrom Macroglobulinemia 2Thymoma 2Sarcoma, Alveolar Soft Part 2Rhabdoid Tumor 2

Interventions

Cyclophosphamide 45Prednisone 31N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 29Vincristine 28Doxorubicin 27Etoposide 22romidepsin 20Gemcitabine 18Lenalidomide 1610-propargyl-10-deazaaminopterin 16fludarabine phosphate 15Whole-Body Irradiation 15Peripheral Blood Stem Cell Transplantation 14Brentuximab Vedotin 13Azacitidine 13Mycophenolic Acid 12Dexamethasone 10Cyclosporine 10Bortezomib 10Alemtuzumab 10Rituximab 8fludarabine 7belinostat 7Methotrexate 6Cytarabine 6Busulfan 6Bendamustine Hydrochloride 6pembrolizumab 5denileukin diftitox 5Nivolumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × selinexor × Clear all
NCT07215832 2026-03-02

KEAP

Karyopharm Therapeutics Inc

Available
GynecologicLymphoidMyeloidPlasma cellSarcoma

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT01607892 2023-01-26

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Karyopharm Therapeutics Inc

Phase 1 Completed
286 enrolled 26 charts
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02314247 2023-01-26

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Karyopharm Therapeutics Inc

Phase 2 Terminated
16 enrolled 16 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT03212937 2021-04-28

Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma

National Cancer Centre, Singapore

Phase 1 Completed
11 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡